Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 6, Issue 4
February 22 2022
Issue Cover

Table of Contents

POINT-COUNTERPOINT

Is a BTKi or BCL2i preferable for first “novel” therapy in CLL? The case for BTKis
Elizabeth A. Brem,Susan O’Brien
View Articletitled, Is a BTKi or BCL2i preferable for first “novel” therapy in CLL? The case for BTKis
Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i
John F. Seymour
View Articletitled, Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i

EXCEPTIONAL CASE REPORTS

Successful treatment and integrated genomic analysis of an infant with FIP1L1-RARA fusion–associated myeloid neoplasm
Oriana Miltiadous,Kseniya Petrova-Drus,Shipra Kaicker,Susan Mathew,Michael Kluk,Julia T. Geyer,Irene Rodriguez-Sanchez,Nancy Bouvier,Giorgio Inghirami,Elliot Stieglitz,Nafa Khedoudja,Ryma Benayed,Michelle Richardson,Wade Anderson,Jamal Benhamida,Daoqi You,Dory Londono,Andrew L. Kung,Susan E. Prockop,Mikhail Roshal,Yanming Zhang,Neerav Shukla
View Articletitled, Successful treatment and integrated genomic analysis of an infant with <em>FIP1L1-RARA</em> fusion–associated myeloid neoplasm
Supplemental data
Eculizumab for refractory thrombosis in antiphospholipid syndrome
Habiba Hussain,Michael D. Tarantino,Shruti Chaturvedi,Keith R. McCrae,Jonathan C. Roberts
View Articletitled, Eculizumab for refractory thrombosis in antiphospholipid syndrome

STIMULUS REPORT

Gata2 +9.5 enhancer regulates adult hematopoietic stem cell self-renewal and T-cell development
Xiaona You,Yun Zhou,Yuan-I Chang,Guangyao Kong,Erik A. Ranheim,Kirby D. Johnson,Alexandra A. Soukup,Emery H. Bresnick,Jing Zhang
View Articletitled, <em>Gata2</em> +9.5 enhancer regulates adult hematopoietic stem cell self-renewal and T-cell development
Supplemental data

CLINICAL TRIALS AND OBSERVATIONS

Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study
Clinical Trials & Observations
Toshko Lissitchkov,Annemieke Willemze,Suresh Katragadda,Kara Rice,Stacey Poloskey,Craig Benson
View Articletitled, Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study
Supplemental data
Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial
Clinical Trials & Observations
Anita W. Rijneveld,Bronno van der Holt,Okke de Weerdt,Bart J. Biemond,Arjen A. van de Loosdrecht,Lotte E. van der Wagen,Mar Bellido,Michel van Gelder,Walter J. F. M. van der Velden,Dominik Selleslag,Daniëlle van Lammeren-Venema,Constantijn J. M. Halkes,Rob Fijnheer,Violaine Havelange,Geerte L. van Sluis,Marie-Cecile Legdeur,Dries Deeren,Alain Gadisseur,Harm A. M. Sinnige,Dimitri A. Breems,Aurélie Jaspers,Ollivier Legrand,Wim E. Terpstra,Rinske S. Boersma,Dominiek Mazure,Agnes Triffet,Lidwine W. Tick,Karolien Beel,Johan A. Maertens,H. Berna Beverloo,Marleen Bakkus,Christa H. E. Homburg,Valerie de Haas,Vincent H. J. van der Velden,Jan J. Cornelissen,the Dutch-Belgian HOVON Cooperative group
View Articletitled, Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial
Supplemental data
Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma
Clinical Trials & Observations
Loretta J. Nastoupil,Collin K. Chin,Jason R. Westin,Nathan H. Fowler,Felipe Samaniego,Xiaoyun Cheng,Man Chun John Ma,Zhiqiang Wang,Fuliang Chu,Ly Dsouza,Chizobam Obi,Jennifer Mims,Lei Feng,Shouhao Zhou,Michael Green,Richard Eric Davis,Sattva S. Neelapu
View Articletitled, Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma
Supplemental data
Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome
Clinical Trials & Observations
Aaron T. Gerds,Bart L. Scott,Peter Greenberg,Tara L. Lin,Daniel A. Pollyea,Amit Verma,Monique Dail,Yuning Feng,Cherie Green,Connie Ma,Bruno C. Medeiros,Mark Yan,Kasra Yousefi,William Donnellan
View Articletitled, Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome
Supplemental data
The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study
Clinical Trials & Observations
John Mascarenhas,Francesco Passamonti,Kate Burbury,Tarec Christoffer El-Galaly,Aaron Gerds,Vikas Gupta,Brian Higgins,Kathrin Wonde,Candice Jamois,Bruno Kovic,Ling-Yuh Huw,Sudhakar Katakam,Margherita Maffioli,Ruben Mesa,Jeanne Palmer,Marta Bellini,David M. Ross,Alessandro M. Vannucchi,Abdulraheem Yacoub
View Articletitled, The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study
Supplemental data
Unrelated donor α/β T cell– and B cell–depleted HSCT for the treatment of pediatric acute leukemia
Clinical Trials & Observations
Allison Barz Leahy,Yimei Li,Julie-An Talano,Caitlin W. Elgarten,Alix E. Seif,Yongping Wang,Bryon Johnson,Dimitri S. Monos,Stephan Kadauke,Timothy S. Olson,Jason Freedman,Lisa Wray,Stephan A. Grupp,Nancy Bunin
View Articletitled, Unrelated donor α/β T cell– and B cell–depleted HSCT for the treatment of pediatric acute leukemia
Supplemental data
Biomarker signatures in cancer patients with and without venous thromboembolism events: a substudy of CASSINI
Clinical Trials & Observations
Alok A. Khorana,John Barnard,Ted Wun,Ujjwala Vijapurkar,CV Damaraju,Kenneth Todd Moore,Peter Wildgoose,Keith R. McCrae
View Articletitled, Biomarker signatures in cancer patients with and without venous thromboembolism events: a substudy of CASSINI
Supplemental data
Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis
Clinical Trials & Observations
Nico Gagelmann,Christine Wolschke,Rachel B. Salit,Thomas Schroeder,Markus Ditschkowski,Victoria Panagiota,Bruno Cassinat,Felicitas Thol,Anita Badbaran,Marie Robin,Hans Christian Reinhardt,Francis Ayuk,Michael Heuser,Bart L. Scott,Nicolaus Kröger
View Articletitled, Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis
Supplemental data
Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study
Clinical Trials & Observations
Gareth P. Gregory,Shaji Kumar,Ding Wang,Daruka Mahadevan,Patricia Walker,Nina Wagner-Johnston,Carolina Escobar,Rajat Bannerji,Divaya Bhutani,Julie Chang,Francisco J. Hernandez-Ilizaliturri,Andreas Klein,John M. Pagel,Witold Rybka,Andrew J. Yee,Anne Mohrbacher,Mo Huang,Mohammed Farooqui,Patricia Marinello,Hang Quach
View Articletitled, Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study
Supplemental data
Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study
Clinical Trials & Observations
Janet L. Kwiatkowski,Mona Hamdy,Amal El-Beshlawy,Fatma S. E. Ebeid,Mohammed Badr,Abdulrahman Alshehri,Julie Kanter,Baba Inusa,Amira A. M. Adly,Suzan Williams,Yurdanur Kilinc,David Lee,Fernando Tricta,Mohsen S. Elalfy
View Articletitled, Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study
Supplemental data
Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma
Clinical Trials & Observations
Timothy J. Voorhees,Beibo Zhao,Jorge Oldan,George Hucks,Amir Khandani,Christopher Dittus,Jennifer Smith,J. Kaitlin Morrison,Catherine J. Cheng,Anastasia Ivanova,Steven Park,Thomas C. Shea,Anne W. Beaven,Gianpietro Dotti,Jonathan Serody,Barbara Savoldo,Natalie Grover
View Articletitled, Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma
Supplemental data
Cardiovascular disease is a leading cause of mortality among TTP survivors in clinical remission
Clinical Trials & Observations
Senthil Sukumar,Max Brodsky,Sarah Hussain,Lisa Yanek,Alison Moliterno,Robert Brodsky,Spero R. Cataland,Shruti Chaturvedi
View Articletitled, Cardiovascular disease is a leading cause of mortality among TTP survivors in clinical remission
Supplemental data
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study
Clinical Trials & Observations
David Martínez-Cuadrón,Juan E. Megías-Vericat,Josefina Serrano,Pilar Martínez-Sánchez,Eduardo Rodríguez-Arbolí,Cristina Gil,Eliana Aguiar,Juan Bergua,José L. López-Lorenzo,Teresa Bernal,Ana Espadana,Mercedes Colorado,Carlos Rodríguez-Medina,María López-Pavía,Mar Tormo,Lorenzo Algarra,María-Luz Amigo,María J. Sayas,Jorge Labrador,Juan I. Rodríguez-Gutiérrez,Celina Benavente,Lissette Costilla-Barriga,Raimundo García-Boyero,Esperanza Lavilla-Rubira,Susana Vives,Pilar Herrera,Daniel García-Belmonte,María Mar Herráez,Graça Vasconcelos Esteves,Maria I. Gómez-Roncero,Ana Cabello,Guiomar Bautista,Amaia Balerdi,José Mariz,Blanca Boluda,Miguel Á. Sanz,Pau Montesinos
View Articletitled, Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study
Supplemental data
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
Clinical Trials & Observations
Constantine S. Tam,Meletios Dimopoulos,Ramon Garcia-Sanz,Judith Trotman,Stephen Opat,Andrew W. Roberts,Roger Owen,Yuqin Song,Wei Xu,Jun Zhu,Jianyong Li,Lugui Qiu,Shirley D’Sa,Wojciech Jurczak,Gavin Cull,Paula Marlton,David Gottlieb,Javier Munoz,Tycel Phillips,Chenmu Du,Meng Ji,Lei Zhou,Haiyi Guo,Hongjie Zhu,Wai Y. Chan,Aileen Cohen,William Novotny,Jane Huang,Alessandra Tedeschi
View Articletitled, Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
Supplemental data

HEALTH SERVICES AND OUTCOMES

Precancer and cancer-associated depression and anxiety among older adults with blood cancers in the United States
Clinical Trials & Observations
Thomas M. Kuczmarski,Tim Jaung,Claire E. Mancuso,Lee Mozessohn,Lizabeth Roemer,Gregory A. Abel,Oreofe O. Odejide
View Articletitled, Precancer and cancer-associated depression and anxiety among older adults with blood cancers in the United States
Supplemental data
Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma
Clinical Trials & Observations
Michel Delforge,Nina Shah,Jesús San F. Miguel,Julia Braverman,Devender S. Dhanda,Ling Shi,Shien Guo,Peiwen Yu,Weiqin Liao,Timothy B. Campbell,Nikhil C. Munshi
View Articletitled, Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma
Supplemental data

LYMPHOID NEOPLASIA

Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001
Clinical Trials & Observations
Thai Hoa Tran,Sylvie Langlois,Caroline Meloche,Maxime Caron,Pascal Saint-Onge,Alexandre Rouette,Alain R. Bataille,Camille Jimenez-Cortes,Thomas Sontag,Henrique Bittencourt,Caroline Laverdière,Vincent-Philippe Lavallée,Jean-Marie Leclerc,Peter D. Cole,Lisa M. Gennarini,Justine M. Kahn,Kara M. Kelly,Bruno Michon,Raoul Santiago,Kristen E. Stevenson,Jennifer J. G. Welch,Kaitlin M. Schroeder,Victoria Koch,Sonia Cellot,Lewis B. Silverman,Daniel Sinnett
View Articletitled, Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001
Supplemental data
Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes
Clinical Trials & Observations
Alessia Castellino,Yucai Wang,Melissa C. Larson,Matthew J. Maurer,Brian K. Link,Umar Farooq,Andrew L. Feldman,Sergei I. Syrbu,Thomas M. Habermann,Jonas Paludo,David J. Inwards,Thomas E. Witzig,Stephen M. Ansell,Cristine Allmer,Susan L. Slager,Jonathon B. Cohen,Peter Martin,James R. Cerhan,Grzegorz S. Nowakowski
View Articletitled, Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes
Supplemental data

MYELOID NEOPLASIA

Momelotinib is a highly potent inhibitor of FLT3-mutant AML
Mohammad Azhar,Zachary Kincaid,Meenu Kesarwani,Arhama Ahmed,Mark Wunderlich,Tahir Latif,Daniel Starczynowski,Mohammad Azam
View Articletitled, Momelotinib is a highly potent inhibitor of FLT3-mutant AML
Supplemental data
European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol
Alex Bataller,Ana Garrido,Francesca Guijarro,Guadalupe Oñate,Marina Diaz-Beyá,Montserrat Arnan,Mar Tormo,Susana Vives,María Paz Queipo de Llano,Rosa Coll,David Gallardo,Ferran Vall-Llovera,Lourdes Escoda,Antonio Garcia-Guiñon,Olga Salamero,Antònia Sampol,Brayan M. Merchan,Joan Bargay,Sandra Castaño-Díez,Daniel Esteban,Aina Oliver-Caldés,Andrea Rivero,Pablo Mozas,Mònica López-Guerra,Marta Pratcorona,Lurdes Zamora,Dolors Costa,Maria Rozman,Josep F. Nomdedéu,Dolors Colomer,Salut Brunet,Jorge Sierra,Jordi Esteve,,on behalf of the Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias (CETLAM)
View Articletitled, European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol
Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

Azacitidine is a potential therapeutic drug for pyridoxine-refractory female X-linked sideroblastic anemia
Yuki Morimoto,Kazuhisa Chonabayashi,Hiroshi Kawabata,Chikako Okubo,Makiko Yamasaki-Morita,Misato Nishikawa,Megumi Narita,Azusa Inagaki,Kayoko Nakanishi,Miki Nagao,Akifumi Takaori-Kondo,Yoshinori Yoshida
View Articletitled, Azacitidine is a potential therapeutic drug for pyridoxine-refractory female X-linked sideroblastic anemia
Supplemental data

TRANSPLANTATION

T-replete HLA-matched grafts vs T-depleted HLA-mismatched grafts in inborn errors of immunity
Clinical Trials & Observations
Su Han Lum,Sinéad Greener,Inigo Perez-Heras,Daniel Drozdov,Rebecca P. Payne,Helen Watson,Kay Carruthers,Robert January,Zohreh Nademi,Stephen Owens,Eleri Williams,Sheila Waugh,Shirelle Burton-Fanning,Timmothy Ronan Leahy,Andrew Cant,Mario Abinun,Terry Flood,Sophie Hambleton,Andrew R. Gennery,Mary Slatter
View Articletitled, T-replete HLA-matched grafts vs T-depleted HLA-mismatched grafts in inborn errors of immunity
Supplemental data
Acute GVHD, BK virus hemorrhagic cystitis and age are risk factors for transplant-associated thrombotic microangiopathy in adults
Clinical Trials & Observations
Sumithira Vasu,Matthew Bostic,Qiuhong Zhao,Nidhi Sharma,Marcin Puto,Samantha Knight,Denise Scott,Rosalyn Guzman,Meghan Kromer,Karen Tackett,Kristin Lind,Kathryn Knill,Emily Watson,Sarah Wall,Ayman Saad,Hannah Choe,Karilyn Larkin,Jonathan Brammer,Samantha Jaglowski,Sam Penza,Stella M. Davies,Spero Cataland
View Articletitled, Acute GVHD, BK virus hemorrhagic cystitis and age are risk factors for transplant-associated thrombotic microangiopathy in adults

RESEARCH LETTER

Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia
Clinical Trials & Observations
Zoe L. Lyski,Myung S. Kim,David Xthona Lee,Hans-Peter Raué,Vikram Raghunathan,Janet Griffin,Debbie Ryan,Amanda E. Brunton,Marcel E. Curlin,Mark K. Slifka,William B. Messer,Stephen E. Spurgeon
View Articletitled, Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia
Supplemental data
All Issues

Advertisement intended for health care professionals

Time to revisit reduced-dose radiotherapy for PCNSL?
Lin A, Brown S, Chinapen S, et al. Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide–based transplant. Blood Adv. 2023;7(23):7153-7160.
Jalink M, Jacobs CF, Khwaja J, et al. Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease. Blood Adv. 2024;8(11):2622-2634.
Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes
Retreatment of multiple myeloma with previously refractory drugs

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals